Scientists develop targeted therapy for T-cell lymphomas and leukemias

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
News-Medical.Net on MSN

Precision immunotherapy for TRBC2-positive T-cell malignancies

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
Mirage News

Johns Hopkins Unveils Targeted T-Cell Cancer Therapy

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell ...
Nature

Improving antibody affinity by mimicking somatic hypermutation in vitro

In vivo affinity maturation of antibodies involves mutation of hot spots in the DNA encoding the variable regions. We have used this information to develop a strategy to improve antibody affinity in ...
Technology Networks

Rethinking Target-Based Drug Discovery: Challenges, Innovations and the Next S-Curve

In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...
Health And Pharma

TRBC2-Specific ADC Shows Robust Efficacy in T-Cell Lymphomas and Leukemias

Researchers have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of ...
pharmaphorum

BARDA backs Locus phage therapy for resistant E coli

The US government has provided almost $24 million in funding to Locus Biosciences to support a mid-stage trial of LBP-EC01, a CRISPR-engineered bacteriophage therapy in development for resistant ...
eLife

Translational reading frame determines the pathogenicity of C-terminal frameshift deletions in MeCP2: an alternative therapeutic approach

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...